Adrienne van den Berg
Overview
Explore the profile of Adrienne van den Berg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
76
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Krayem M, Aftimos P, Najem A, van den Hooven T, van den Berg A, Hovestad-Bijl L, et al.
Cancers (Basel)
. 2024 Jul;
16(14).
PMID: 39061253
In the original article [...].
2.
Hilhorst R, van den Berg A, Boender P, van Wezel T, Kievits T, de Wijn R, et al.
Cancers (Basel)
. 2023 Sep;
15(18).
PMID: 37760447
Differentiated non-medullary thyroid cancer (NMTC) can be effectively treated by surgery followed by radioactive iodide therapy. However, a small subset of patients shows recurrence due to a loss of iodide...
3.
Buffart T, van den Oord R, van den Berg A, Hilhorst R, Bastiaensen N, Pruijt H, et al.
Clin Proteomics
. 2021 Feb;
18(1):8.
PMID: 33602116
Background: Based on their potential to analyze aberrant cellular signaling in relation to biological function, kinase activity profiling in tumor biopsies by peptide microarrays and mass spectrometry-based phosphoproteomics may guide...
4.
Tabbo F, Guerrera F, van den Berg A, Gaudiano M, Maletta F, Bessone L, et al.
Eur J Cancer
. 2020 Dec;
144:17-30.
PMID: 33316635
Introduction: High fidelity between non-small cell lung cancer (NSCLC) primary tumours and patient-derived tumour xenografts (PDTXs) is of paramount relevance to spur their application. Extensive proteomic and kinomic analysis of...
5.
Krayem M, Aftimos P, Najem A, van den Hooven T, van den Berg A, Hovestad-Bijl L, et al.
Cancers (Basel)
. 2020 Oct;
12(10).
PMID: 33066704
The authors would like to make a correction to their published paper [...].
6.
Krayem M, Aftimos P, Najem A, van den Hooven T, van den Berg A, Hovestad-Bijl L, et al.
Cancers (Basel)
. 2020 Feb;
12(2).
PMID: 32098410
Mitogen-activated protein kinase (MAPK) inhibition with the combination of BRAF (Rapidly Accelerated Fibrosarcoma) and MEK (Mitogen-activated protein kinase kinase) inhibitors has become the standard of first-line therapy of metastatic melanoma...
7.
Hilhorst R, Houkes L, Mommersteeg M, Musch J, van den Berg A, Ruijtenbeek R
Methods Mol Biol
. 2013 Feb;
977:259-71.
PMID: 23436369
Peptide microarray technology can be used to identify substrates for recombinant kinases, to measure kinase activity and changes thereof in cell lysates and lysates from fresh frozen (tumor) tissue. The...
8.
Poot A, van Ameijde J, Slijper M, van den Berg A, Hilhorst R, Ruijtenbeek R, et al.
Chembiochem
. 2009 Jul;
10(12):2042-51.
PMID: 19618415
Kinase inhibitors are increasingly important in drug development. Because the majority of current inhibitors target the conserved ATP-binding site, selectivity might become an important issue. This could be particularly problematic...
9.
Hilhorst R, Houkes L, van den Berg A, Ruijtenbeek R
Anal Biochem
. 2009 Apr;
387(2):150-61.
PMID: 19344656
A microarray-based mix-and-measure, nonradioactive multiplex method with real-time detection was used for substrate identification, assay development, assay optimisation, and kinetic characterization of protein kinase A (PKA). The peptide arrays included...